Bringing a Gene-Activated Bone Substitute Into Clinical Practice: From Bench to Bedside.

ABSTRACT: Bone grafting and reconstruction are still challenging in clinical practice because of the limitations of bone autografts and the drawbacks of currently approved bone substitutes. We thus developed a gene-activated bone substitute based on octacalcium phosphate and naked plasmid DNA carrying the vascular endothelial growth factor gene. This advanced combined therapy medicinal product had no cytotoxic effects in vitro, slightly decreased bone marrow mesenchymal stromal cell (MSC) doubling time, and was characterized by a prolonged level of gene construct delivery in vivo in a luciferase bioimaging assay. In the model of critically sized cranial bone defects in rabbits, the gene-activated matrix increased bone tissue formation through angiogenesis induction. After preclinical s

SUBMITTER: Bozo IY 

PROVIDER: S-EPMC7889956 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature